Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential As A Precision Medicine For Cancer
Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential As A Precision Medicine For Cancer
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma -
- 新型CDK2/9抑制劑fadraciclib單藥治療研究中的臨床、PK和PD數據支持進行中的概念證明研究，該研究針對實體腫瘤和淋巴瘤患者 -
BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the CYC065-101 study of fadraciclib as oral monotherapy was presented at a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago, IL. See link to poster here.
2024年6月3日，新澤西州伯克利高地（GLOBE NEWSWIRE）——生物製藥公司Cyclacel Pharmaceuticals, Inc.（納斯達克:CYCC,納斯達克:CYCCP，“Cyclacel”或“公司”），開發基於癌細胞生物學的創新藥物，今天宣佈，CYC065-101研究的fadraciclib作爲口服單一療法的新臨床、藥代動力學（PK）和藥效學（PD）數據已於2024年5月31日至6月4日的美國臨床腫瘤學會（ASCO）年會上作爲展板展示，地點位於伊利諾伊州芝加哥。點擊這裏查看海報。
譯文內容由第三人軟體翻譯。